Samantha Galluzzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samantha Galluzzi has a total of 605 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Battista Frisoni
Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland
56 shared publications - Cristina Geroldi
IRCCS “S. Giovanni di Dio-F.B.F.”, Brescia, Italy
19 shared publications Giovanni B. Frisoni
Memory center, Geneva University and University Hospitals, Geneva, Switzerland
15 shared publications- Orazio Zanetti
IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
13 shared publications - Magda Tsolaki
1st Department of Neurology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
12 shared publications - Flavio Nobili
IRCCS Ospedale Policlinico San Martino, Genoa, Italy
11 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by Springer Nature in Mindfulness
- Vol. 17 (1) , 1-25
The Effects of Mindfulness-Based Interventions on Physiological Markers of Stress in Older Adults: A Systematic Review and Synthesis
- 2 December 2025
- Published by Springer Nature in Mindfulness
- Vol. 17 (1) , 1-25
Open AccessThe Effects of Mindfulness-Based Interventions on Physiological Markers of Stress in Older Adults: A Systematic Review and Synthesis
- Open Access
- 14 May 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-13
Targeting brain health in subjective cognitive decline: insights from a multidomain randomized controlled trial
Background Multidomain lifestyle interventions are a promising approach to prevent cognitive decline, but their effects in subjective cognitive decline (SCD) remain controversial. We investigated the effects of lifestyle interventions on cognition and brain integrity in these at-risk individuals. Methods One-hundred twenty-eight older adults with SCD were randomly assigned to either Active Control Intervention (ACI), i.e. health education; Partial Intervention (PI), i.e. tramiprosate supplementation (100 mg/die) and dietary advice; or Multilevel Intervention (MI), i.e. PI plus computerized cognitive training and physical exercise, for one year. Neuropsychological assessment and MRI were performed at baseline and at 1-year follow-up. Analyses of covariance were used to measure the effects of interventions on predefined outcomes. Results The MI group significantly improved in attention-executive functioning (p = 0.003) compared to ACI (Cohen’s d: 0.47, 95% CI 0.13–0.79). In addition, depressive symptoms (Cohen’s d: – 0.48, 95% C.I. – 0.81 to – 0.14) and memory concerns (Cohen’s d: – 0.77, 95% C.I. – 1.12 to – 0.41) decreased in the MI and PI respectively, relative to the ACI. The MI group also showed increased resting-state (i.e., intrinsic) brain activity in the right fronto-parietal executive network. No significant intervention effects on brain structural or vascular outcomes were found. Conclusion The study shows that a multidomain lifestyle intervention can enhance attention-executive function, ameliorate depressive symptoms and increase functional connectivity in SCD. These findings support the role of lifestyle interventions in public health strategies to mitigate cognitive decline risk. Trial registration The trial has been registered at the United States National Library of Medicine at the National Institutes of Health Registry of Clinical Trials under the code NCT04744922 on December 9th, 2017 (https://www.clinicaltrials.gov/ct2/show/NCT03382353).
- 14 May 2025
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-13
Open AccessTargeting brain health in subjective cognitive decline: insights from a multidomain randomized controlled trial
Background Multidomain lifestyle interventions are a promising approach to prevent cognitive decline, but their effects in subjective cognitive decline (SCD) remain controversial. We investigated the effects of lifestyle interventions on cognition and brain integrity in these at-risk individuals. Methods One-hundred twenty-eight older adults with SCD were randomly assigned to either Active Control Intervention (ACI), i.e. health education; Partial Intervention (PI), i.e. tramiprosate supplementation (100 mg/die) and dietary advice; or Multilevel Intervention (MI), i.e. PI plus computerized cognitive training and physical exercise, for one year. Neuropsychological assessment and MRI were performed at baseline and at 1-year follow-up. Analyses of covariance were used to measure the effects of interventions on predefined outcomes. Results The MI group significantly improved in attention-executive functioning (p = 0.003) compared to ACI (Cohen’s d: 0.47, 95% CI 0.13–0.79). In addition, depressive symptoms (Cohen’s d: – 0.48, 95% C.I. – 0.81 to – 0.14) and memory concerns (Cohen’s d: – 0.77, 95% C.I. – 1.12 to – 0.41) decreased in the MI and PI respectively, relative to the ACI. The MI group also showed increased resting-state (i.e., intrinsic) brain activity in the right fronto-parietal executive network. No significant intervention effects on brain structural or vascular outcomes were found. Conclusion The study shows that a multidomain lifestyle intervention can enhance attention-executive function, ameliorate depressive symptoms and increase functional connectivity in SCD. These findings support the role of lifestyle interventions in public health strategies to mitigate cognitive decline risk. Trial registration The trial has been registered at the United States National Library of Medicine at the National Institutes of Health Registry of Clinical Trials under the code NCT04744922 on December 9th, 2017 (https://www.clinicaltrials.gov/ct2/show/NCT03382353).
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
A clinical trial of cognitive and biological effects of citrus phytochemicals in subjective cognitive decline: baseline sociodemographic, clinical, and cognitive characteristics
Background: We designed a clinical trial to evaluate cognitive and biological effects of a 36‐week treatment with citrus peel extract in older adults with subjective cognitive decline (SCD) (ClinicalTrials.gov identifier: NCT04744922). Here we present baseline sociodemographic, clinical, and cognitive characteristics of the enrolled subjects.Method: Eighty subjects were enrolled between April 2021 and August 2022, and randomly assigned to receive either active treatment (400 mg citrus peel extract standardized in content of auraptene ‐ 0.1 mg ‐ and naringenin – 3 mg) or placebo in a 1:1 ratio for 36 weeks. Data about nutritional state and comorbidity, current therapy, health‐related behaviours, cognitive performance on verbal and non‐verbal memory, attention, executive and visuospatial functions were collected. Differences between groups (termed group A and B to avoid unblinding – the treatment allocation is unknown to the investigators) were compared using independent t‐test or Fisher’s exact test.Result: The enrolled subjects have a mean age of 69.2±4.3 years, a high level of education (mean 13.7±3.5 years) and a higher prevalence of females (75%), with no significant differences between groups A and B. Nutritional state and comorbidity were similar (Body Mass Index: 25.1±4.8 vs 24.0±3.9, p = .27 and Cumulative Illness Rating Scale: 1.46±0.22 vs 1.51±0.24, p = .38, groups A and B, respectively). The most frequent concurrent therapies included cardiovascular system and alimentary tract and metabolism drugs, with no significant differences between A and B (55% vs 63%, p = .32; 61% vs 66%, p = .41, respectively). Health‐related behaviours were also similar between A and B (Mediterranean Diet Adherence Screener: 9.0±1.9 vs 8.8±1.8; Smoking: 13% vs 8%; Alcohol consumption: wine 81% vs 83%, coffee consumption 93% vs 88%, all p = >.30). Cognitive scores were all within the normal range and similar between groups, except for the Wisconsin Card Sorting test total score, where group A performed marginally better than group B (27.9±21.6 vs 40.7±32.2, p = .049).Conclusion: The trial is expected to complete the longitudinal assessment in April 2023. The results of this trial will enable to evaluate the efficacy of citrus phytochemicals in SCD, informing the design of future nutritional interventions in people at risk of decline cognitive.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S21)
Open AccessA clinical trial of cognitive and biological effects of citrus phytochemicals in subjective cognitive decline: baseline sociodemographic, clinical, and cognitive characteristics
Background: We designed a clinical trial to evaluate cognitive and biological effects of a 36‐week treatment with citrus peel extract in older adults with subjective cognitive decline (SCD) (ClinicalTrials.gov identifier: NCT04744922). Here we present baseline sociodemographic, clinical, and cognitive characteristics of the enrolled subjects.Method: Eighty subjects were enrolled between April 2021 and August 2022, and randomly assigned to receive either active treatment (400 mg citrus peel extract standardized in content of auraptene ‐ 0.1 mg ‐ and naringenin – 3 mg) or placebo in a 1:1 ratio for 36 weeks. Data about nutritional state and comorbidity, current therapy, health‐related behaviours, cognitive performance on verbal and non‐verbal memory, attention, executive and visuospatial functions were collected. Differences between groups (termed group A and B to avoid unblinding – the treatment allocation is unknown to the investigators) were compared using independent t‐test or Fisher’s exact test.Result: The enrolled subjects have a mean age of 69.2±4.3 years, a high level of education (mean 13.7±3.5 years) and a higher prevalence of females (75%), with no significant differences between groups A and B. Nutritional state and comorbidity were similar (Body Mass Index: 25.1±4.8 vs 24.0±3.9, p = .27 and Cumulative Illness Rating Scale: 1.46±0.22 vs 1.51±0.24, p = .38, groups A and B, respectively). The most frequent concurrent therapies included cardiovascular system and alimentary tract and metabolism drugs, with no significant differences between A and B (55% vs 63%, p = .32; 61% vs 66%, p = .41, respectively). Health‐related behaviours were also similar between A and B (Mediterranean Diet Adherence Screener: 9.0±1.9 vs 8.8±1.8; Smoking: 13% vs 8%; Alcohol consumption: wine 81% vs 83%, coffee consumption 93% vs 88%, all p = >.30). Cognitive scores were all within the normal range and similar between groups, except for the Wisconsin Card Sorting test total score, where group A performed marginally better than group B (27.9±21.6 vs 40.7±32.2, p = .049).Conclusion: The trial is expected to complete the longitudinal assessment in April 2023. The results of this trial will enable to evaluate the efficacy of citrus phytochemicals in SCD, informing the design of future nutritional interventions in people at risk of decline cognitive.
- Open Access
- 8 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3177
Disclosure of Genetic Risk Factors for Alzheimer’s Disease to Cognitively Healthy Individuals—From Current Practice towards a Personalised Medicine Scenario
Alzheimer’s disease (AD) is a genetically complex disorder. In addition to the relatively small number of pathogenic variants causing autosomal dominant AD, many others have been associated with the much more common sporadic form. The E4 allele of the Apolipoprotein E (APOE) is the first discovered genetic risk factor for AD. In addition, more than 70 genetic risk loci contributing to AD have been identified. Current guidelines do not recommend AD susceptibility genetic testing in cognitively healthy adults because the implications for clinical care are limited. However, secondary prevention clinical trials of disease-modifying therapies enrol individuals based on genetic criteria, and participants are often informed of APOE testing results. Moreover, the availability of direct-to-consumer genetic testing allows individuals to learn their own AD genetic risk profile without medical supervision. A number of research protocols for AD susceptibility genetic testing have been proposed. In Italy, disclosure processes and protocols beyond those developed for inherited dementia have not been established yet. We reviewed the literature on the current practice and clinical issues related to disclosing AD genetic risk to cognitively healthy individuals and provide suggestions that may help to develop specific guidelines at the national level.
- 8 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3177
Open AccessDisclosure of Genetic Risk Factors for Alzheimer’s Disease to Cognitively Healthy Individuals—From Current Practice towards a Personalised Medicine Scenario
Alzheimer’s disease (AD) is a genetically complex disorder. In addition to the relatively small number of pathogenic variants causing autosomal dominant AD, many others have been associated with the much more common sporadic form. The E4 allele of the Apolipoprotein E (APOE) is the first discovered genetic risk factor for AD. In addition, more than 70 genetic risk loci contributing to AD have been identified. Current guidelines do not recommend AD susceptibility genetic testing in cognitively healthy adults because the implications for clinical care are limited. However, secondary prevention clinical trials of disease-modifying therapies enrol individuals based on genetic criteria, and participants are often informed of APOE testing results. Moreover, the availability of direct-to-consumer genetic testing allows individuals to learn their own AD genetic risk profile without medical supervision. A number of research protocols for AD susceptibility genetic testing have been proposed. In Italy, disclosure processes and protocols beyond those developed for inherited dementia have not been established yet. We reviewed the literature on the current practice and clinical issues related to disclosing AD genetic risk to cognitively healthy individuals and provide suggestions that may help to develop specific guidelines at the national level.
- Open Access
- 17 October 2022
- Published by Springer Nature in Nutrition Journal
- Vol. 21 (1) , 1-11
Cognitive and biological effects of citrus phytochemicals in subjective cognitive decline: a 36-week, randomized, placebo-controlled trial
Background: Auraptene (AUR) and naringenin (NAR) are citrus-derived phytochemicals that influence several biological mechanisms associated with cognitive decline, including neuronal damage, oxidative stress and inflammation. Clinical evidence of the efficacy of a nutraceutical with the potential to enhance cognitive function in cohorts at risk of cognitive decline would be of great value from a preventive perspective. The primary aim of this study is to determine the cognitive effects of a 36-week treatment with citrus peel extract standardized in levels of AUR and NAR in older adults experiencing subjective cognitive decline (SCD). The secondary aim is to determine the effects of these phytochemicals on blood-based biomarkers indicative of neuronal damage, oxidative stress, and inflammation.Methods: Eighty older persons with SCD will be recruited and randomly assigned to receive the active treatment (400 mg of citrus peel extract containing 0.1 mg of AUR and 3 mg of NAR) or the placebo at a 1:1 ratio for 36 weeks. The primary endpoint is a change in the Repeatable Battery for the Assessment of Neuropsychological Status score from baseline to weeks 18 and 36. Other cognitive outcomes will include changes in verbal and nonverbal memory, attention, executive and visuospatial functions. Blood samples will be collected from a consecutive subsample of 60 participants. The secondary endpoint is a change in interleukin-8 levels over the 36-week period. Other biological outcomes include changes in markers of neuronal damage, oxidative stress, and pro- and anti-inflammatory cytokines.Conclusion: This study will evaluate whether an intervention with citrus peel extract standardized in levels of AUR and NAR has cognitive and biological effects in older adults with SCD, facilitating the establishment of nutrition intervention in people at risk of cognitive decline.Trial registration: The trial is registered with the United States National Library of Medicine at the National Institutes of Health Registry of Clinical Trials under the code NCT04744922 on February 9th, 2021 (https://www.clinicaltrials.gov/ct2/show/NCT04744922).
- 17 October 2022
- Published by Springer Nature in Nutrition Journal
- Vol. 21 (1) , 1-11
Open AccessCognitive and biological effects of citrus phytochemicals in subjective cognitive decline: a 36-week, randomized, placebo-controlled trial
Background: Auraptene (AUR) and naringenin (NAR) are citrus-derived phytochemicals that influence several biological mechanisms associated with cognitive decline, including neuronal damage, oxidative stress and inflammation. Clinical evidence of the efficacy of a nutraceutical with the potential to enhance cognitive function in cohorts at risk of cognitive decline would be of great value from a preventive perspective. The primary aim of this study is to determine the cognitive effects of a 36-week treatment with citrus peel extract standardized in levels of AUR and NAR in older adults experiencing subjective cognitive decline (SCD). The secondary aim is to determine the effects of these phytochemicals on blood-based biomarkers indicative of neuronal damage, oxidative stress, and inflammation.Methods: Eighty older persons with SCD will be recruited and randomly assigned to receive the active treatment (400 mg of citrus peel extract containing 0.1 mg of AUR and 3 mg of NAR) or the placebo at a 1:1 ratio for 36 weeks. The primary endpoint is a change in the Repeatable Battery for the Assessment of Neuropsychological Status score from baseline to weeks 18 and 36. Other cognitive outcomes will include changes in verbal and nonverbal memory, attention, executive and visuospatial functions. Blood samples will be collected from a consecutive subsample of 60 participants. The secondary endpoint is a change in interleukin-8 levels over the 36-week period. Other biological outcomes include changes in markers of neuronal damage, oxidative stress, and pro- and anti-inflammatory cytokines.Conclusion: This study will evaluate whether an intervention with citrus peel extract standardized in levels of AUR and NAR has cognitive and biological effects in older adults with SCD, facilitating the establishment of nutrition intervention in people at risk of cognitive decline.Trial registration: The trial is registered with the United States National Library of Medicine at the National Institutes of Health Registry of Clinical Trials under the code NCT04744922 on February 9th, 2021 (https://www.clinicaltrials.gov/ct2/show/NCT04744922).
- Open Access
- 16 March 2022
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 36 (2) , 118-124
Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia
Aim: Our aim was to evaluate the psychological impact of predictive genetic testing in individuals at-risk for inherited dementia who underwent a structured counseling and testing protocol. Methods: Participants were healthy at-risk relatives from families with at least one affected patient, in whom a disease-associated genetic variant had been ascertained. A comprehensive psychological assessment (personality, anxiety and depression, quality of life, coping strategies, resilience and health-related beliefs) was administered at baseline, at 6 months and 12 months follow-up. Results: Twenty-four participants from 13 families were included. Sixteen participants underwent blood sampling and genetic analysis; 6 resulted to be carriers of pathogenic variants (1 in PSEN1, 1 in PSEN2, 4 in GRN). Carriers showed higher score on the Resilience Scale for Adults (RSA) – social competence, and on Multidimensional Health Locus of Control – internal, than noncarriers (P=0.03 for both). Ten at-risk relatives who completed the follow-up showed improvement in RSA – planned future (P=0.01) with respect to baseline. Discussion: Our case series showed that at-risk individuals undergoing predictive testing showed benefit on personal life and no detrimental impact on a broad range of psychological outcomes. Higher social skills and lower internal health locus of control in carriers may be an early psychological correlate of preclinical dementia.
- 16 March 2022
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 36 (2) , 118-124
Open AccessPsychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia
Aim: Our aim was to evaluate the psychological impact of predictive genetic testing in individuals at-risk for inherited dementia who underwent a structured counseling and testing protocol. Methods: Participants were healthy at-risk relatives from families with at least one affected patient, in whom a disease-associated genetic variant had been ascertained. A comprehensive psychological assessment (personality, anxiety and depression, quality of life, coping strategies, resilience and health-related beliefs) was administered at baseline, at 6 months and 12 months follow-up. Results: Twenty-four participants from 13 families were included. Sixteen participants underwent blood sampling and genetic analysis; 6 resulted to be carriers of pathogenic variants (1 in PSEN1, 1 in PSEN2, 4 in GRN). Carriers showed higher score on the Resilience Scale for Adults (RSA) – social competence, and on Multidimensional Health Locus of Control – internal, than noncarriers (P=0.03 for both). Ten at-risk relatives who completed the follow-up showed improvement in RSA – planned future (P=0.01) with respect to baseline. Discussion: Our case series showed that at-risk individuals undergoing predictive testing showed benefit on personal life and no detrimental impact on a broad range of psychological outcomes. Higher social skills and lower internal health locus of control in carriers may be an early psychological correlate of preclinical dementia.
- 1 May 2020
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 32 (5) , 817-826
Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study
Background Alzheimer’s Disease (AD) is a multifactorial disorder driven by genetic and modifiable lifestyle risk factors. Lifestyle primary prevention initiatives may reduce the prevalence and incidence of dementia in older adults. Objectives The E.Mu.N.I study is a randomized controlled trial investigating the effect of multilevel non-pharmacologic interventions on cognitive performances (primary outcome) and structural and vascular brain MRI markers (secondary outcome), as well as markers of brain functional connectivity change (exploratory outcome), in older adults with subjective memory decline (SMD). Here, we present the study design and the baseline features of the sample. Methods Cognitively intact older adults with SMD, enrolled between February 2016 and June 2017, were randomly assigned to one of the 3 interventions for 1 year: Active Control Intervention (ACI), i.e., educational lessons; Partial Intervention (PI), i.e., homotaurine administration (100 mg/die) and lessons on the Mediterranean diet; Multilevel Intervention (MI), i.e., PI plus computerized cognitive training and physical exercise training. Results One-hundred and twenty-eight eligible participants were enrolled (66% female; age: 68 ± 5 years). Eighty-two percent of the sample was composed of volunteers with SMD from the community. Participants were randomly allocated to the interventions as follows: ACI (N = 40), PI (N = 44), MI (N = 44). No significant differences among groups emerged on socio-demographic, clinical–neuropsychological variables and MRI markers at baseline. Conclusions The outcomes obtained from the E.Mu.N.I. study will clarify the efficacy of multilevel non-pharmacologic interventions on cognitive and neuroimaging markers in SMD individuals. This is a crucial step forward for the development of cost-effective non-pharmacologic primary prevention initiatives for AD.
- 1 May 2020
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 32 (5) , 817-826
Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study
Background Alzheimer’s Disease (AD) is a multifactorial disorder driven by genetic and modifiable lifestyle risk factors. Lifestyle primary prevention initiatives may reduce the prevalence and incidence of dementia in older adults. Objectives The E.Mu.N.I study is a randomized controlled trial investigating the effect of multilevel non-pharmacologic interventions on cognitive performances (primary outcome) and structural and vascular brain MRI markers (secondary outcome), as well as markers of brain functional connectivity change (exploratory outcome), in older adults with subjective memory decline (SMD). Here, we present the study design and the baseline features of the sample. Methods Cognitively intact older adults with SMD, enrolled between February 2016 and June 2017, were randomly assigned to one of the 3 interventions for 1 year: Active Control Intervention (ACI), i.e., educational lessons; Partial Intervention (PI), i.e., homotaurine administration (100 mg/die) and lessons on the Mediterranean diet; Multilevel Intervention (MI), i.e., PI plus computerized cognitive training and physical exercise training. Results One-hundred and twenty-eight eligible participants were enrolled (66% female; age: 68 ± 5 years). Eighty-two percent of the sample was composed of volunteers with SMD from the community. Participants were randomly allocated to the interventions as follows: ACI (N = 40), PI (N = 44), MI (N = 44). No significant differences among groups emerged on socio-demographic, clinical–neuropsychological variables and MRI markers at baseline. Conclusions The outcomes obtained from the E.Mu.N.I. study will clarify the efficacy of multilevel non-pharmacologic interventions on cognitive and neuroimaging markers in SMD individuals. This is a crucial step forward for the development of cost-effective non-pharmacologic primary prevention initiatives for AD.
- 4 January 2020
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 14 (6) , 2594-2605
Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer’s disease
Age at symptom onset (AAO) underlies different Alzheimer’s disease (AD) clinical variants: late-onset AD (LOAD) is characterized by memory deficits, while early-onset AD (EOAD) presents predominantly with non-memory symptoms. The involvement of different neural networks may explain these distinct clinical phenotypes. In this study, we tested the hypothesis of an early and selective involvement of neural networks based on AAO in AD. Twenty memory clinic patients with prodromal AD (i.e., mild cognitive impairment with an AD-like cerebrospinal fluid profile) and 30 healthy controls underwent a cognitive evaluation and a resting state functional MRI exam. Independent component analysis was performed to assess functional connectivity (FC) in the following networks: default mode, frontoparietal, limbic, visual, and sensorimotor. Patients were stratified into late-onset (pLOAD) and early-onset (pEOAD) prodromal AD according to the AAO and controls were stratified into younger and older groups accordingly. Decreased FC within the default mode and the limbic networks was observed in pLOAD, while pEOAD showed lower FC in the frontoparietal and visual networks. The sensorimotor network did not show differences between groups. A significant association was found between memory and limbic network FC in pLOAD, and between executive functions and frontoparietal network FC in pEOAD, although the latter association did not survive multiple comparison correction. Our findings indicate that aberrant connectivity in memory networks is associated with pLOAD, while networks underlying executive and visuo-spatial functions are affected in pEOAD. These findings are in line with the hypothesis that the pathophysiological mechanisms underlying EOAD and LOAD are distinct.
- 4 January 2020
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 14 (6) , 2594-2605
Age at onset reveals different functional connectivity abnormalities in prodromal Alzheimer’s disease
Age at symptom onset (AAO) underlies different Alzheimer’s disease (AD) clinical variants: late-onset AD (LOAD) is characterized by memory deficits, while early-onset AD (EOAD) presents predominantly with non-memory symptoms. The involvement of different neural networks may explain these distinct clinical phenotypes. In this study, we tested the hypothesis of an early and selective involvement of neural networks based on AAO in AD. Twenty memory clinic patients with prodromal AD (i.e., mild cognitive impairment with an AD-like cerebrospinal fluid profile) and 30 healthy controls underwent a cognitive evaluation and a resting state functional MRI exam. Independent component analysis was performed to assess functional connectivity (FC) in the following networks: default mode, frontoparietal, limbic, visual, and sensorimotor. Patients were stratified into late-onset (pLOAD) and early-onset (pEOAD) prodromal AD according to the AAO and controls were stratified into younger and older groups accordingly. Decreased FC within the default mode and the limbic networks was observed in pLOAD, while pEOAD showed lower FC in the frontoparietal and visual networks. The sensorimotor network did not show differences between groups. A significant association was found between memory and limbic network FC in pLOAD, and between executive functions and frontoparietal network FC in pEOAD, although the latter association did not survive multiple comparison correction. Our findings indicate that aberrant connectivity in memory networks is associated with pLOAD, while networks underlying executive and visuo-spatial functions are affected in pEOAD. These findings are in line with the hypothesis that the pathophysiological mechanisms underlying EOAD and LOAD are distinct.
- 1 November 2019
- Published by Elsevier in The Lancet Neurology
- Vol. 18 (11) , 1034-1044
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
- 1 November 2019
- Published by Elsevier in The Lancet Neurology
- Vol. 18 (11) , 1034-1044
Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study
- 2 July 2019
- Published by Springer Nature in Journal of Neurology
- Vol. 266 (10) , 2535-2545
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset
The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer’s biomarkers in a large sample of patients with mild cognitive impairment (MCI).
- 2 July 2019
- Published by Springer Nature in Journal of Neurology
- Vol. 266 (10) , 2535-2545
Prognostic value of Alzheimer’s biomarkers in mild cognitive impairment: the effect of age at onset
The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer’s biomarkers in a large sample of patients with mild cognitive impairment (MCI).